CELL INTELLIGENCE · 肿瘤细胞治疗研究

Inclusion Criteria:

* 1\. Age range of 18-70 years old, gender not limited;
* 2\. Expected survival time exceeds 12 weeks;
* 3\. Diagnosed with blood system tumors such as CD20+B-cell lymphoma or lymphocytic leukemia and meeting the corresponding previous treatment requirements;
* 4\. There are assessable lesions (applicable only to lymphoma patients);
* 5\. The physical fitness status score of the Eastern Cancer Collaboration Group (ECOG) is 0 or 1 point; Before screening (at baseline), corresponding requirements should be met;
* 7\. Male and female patients of appropriate age must use reliable methods of contraception before entering the trial, during the research process until 30 days after discontinuation of medication; Reliable contraceptive methods will be determined by the primary researchers or designated personnel;
* 8\. Those who can understand this experiment and have signed the informed consent form.

Exclusion Criteria:

* 1\. Accompanied by other uncontrolled malignant tumors;
* 2\. Received chimeric antigen receptor therapy or other transgenic T cell therapy within 6 months;
* 3\. Known history of HIV or hepatitis B (HBsAg positive and HBV DNA reaching the detection limit) or hepatitis C virus (anti HCV positive) infection;
* 4\. Participants with a history of CNS lymphoma, malignant cells in cerebrospinal fluid, or brain metastases;
* 5\. Participants with atrial or ventricular involvement;
* 6\. Emergency treatment is required due to the impact of tumor masses, such as intestinal obstruction or vascular compression;
* 7\. Suffering from serious diseases such as coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, cerebral thrombosis, cerebral hemorrhage, poorly controlled hypertension, or other uncontrolled active diseases that hinder participation in the trial;
* 8\. Unstable pulmonary embolism, deep vein thrombosis, or other major arterial/venous thromboembolism events occurred within 30 days prior to enrollment. If receiving anticoagulant therapy, the treatment dose of participants must reach a stable level before enrollment;
* 9\. For those who have been using immunosuppressants for a long time after organ transplantation, except for recent or current inhaled corticosteroid therapy;
* 10\. Any pregnant or breastfeeding woman, or participant who plans to conceive during or within 18 months after treatment;
* 11\. Within 14 days prior to enrollment, there is an active or uncontrollable infection that requires systemic treatment (excluding simple urinary tract infections or upper respiratory tract infections).
* 12\. The researcher believes that there are any other factors that are not suitable for the study participants to enter this trial.

主要终点：Dose limiting toxicity (DLT) · Within 28 days after the initial treatment；The incidence of adverse effects · Through study completion, an average of 2 years；Maximum tolerated dose (MTD) or optimal biological dose (OBD) · Through study completion, an average of 2 years
次要终点：0bjective response rate (ORR)；Disease control rate (DCR)；Duration of response (DoR)；Progression free survival (PFS)

• in vivo CAR-T drug, Escalation doses · EXPERIMENTAL · In vivo CAR-T drug targeting CD20 based on mRNA-LNP
• in vivo CAR-T drug, Extended doses · EXPERIMENTAL · In vivo CAR-T drug targeting CD20 based on mRNA-LNP

Malignant hematological tumors mainly derived from adult B cells are mainly acute lymphoblastic leukemia (ALL) and non Hodgkin lymphoma (NHL). Overall, although existing therapies have significantly improved the survival rates of most patients, the treatment of relapsed/refractory patients still faces significant challenges. CD20 is a transmembrane protein highly expressed on the surface of B cells, almost penetrating the precursor, mature, and activated stages of B cells, but lacking in plasma cells, making it an ideal target for B cell malignancies. In recent years, the breakthrough development of in vivo CAR-T therapy has overturned the traditional paradigm of in vitro CAR-T technology. The core principle is to directly deliver the gene encoding chimeric antigen receptor (CAR) to T cells in the patient's body through gene delivery vectors, without the need for in vitro isolation, modification, and amplification processes, and to complete the gene reprogramming of T cells in vivo. At present, the mainstream carrier technologies for CAR-T therapy in vivo are divided into two categories: lentiviral carriers and lipid nanoparticle (LNP) carriers. LNP carriers have significantly broken through the clinical bottlenecks of traditional CAR-T in terms of cost and accessibility, safety, and timeliness. This experimental drug is a CD20 based messenger ribonucleic acid (mRNA) therapeutic drug, which is an injection formed by loading mRNA onto lipid nanoparticles (LNP). It has shown efficient B-cell clearance activity and good safety in non clinical settings, supporting further clinical exploration in B-cell hematological malignancies. It is expected to provide an innovative, safe, and accessible immunotherapy for B-cell hematological malignancies and bring better clinical benefits to more patients with B-cell hematological malignancies.